BRIEF — Elevar Therapeutics Resubmits NDA To FDA For Combination Of Camrelizumab Plus Rivoceranib

Oct 14 (Reuters) — ELEVAR THERAPEUTICS: Elevar Therapeutics Resubmits New Drug Application To Fda For Combination Of Camrelizumab Plus Rivoceranib For Use As A First-line Treatment Option For Unresectable Or Metastatic Hepatocellular Carcinoma (Reuters.Briefs@thomsonreuters.com;)